Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas'. The following are the o... Read More
Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More
Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ... Read More
Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ... Read More
Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in hy... Read More
Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascim... Read More
Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with... Read More
Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2 arm parallel-group, double-blind, placebo... Read More
Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxe... Read More
Singapore, Aug. 18 -- The Health Sciences Authority received information related to the study titled 'A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC ... Read More